As of 2024-12-13, the EV/EBITDA ratio of Arbutus Biopharma Corp (ABUS) is -8.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Arbutus's latest enterprise value is 642.74 mil USD. Arbutus's TTM EBITDA according to its financial statements is -78.11 mil USD. Dividing these 2 quantities gives us the above Arbutus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.0x | 16.0x |
| Forward P/E multiples | 15.4x - 21.2x | 15.7x |
| Fair Price | (6.18) - (6.82) | (6.37) |
| Upside | -273.6% - -291.7% | -278.8% |
| Date | EV/EBITDA |
| 2024-12-11 | -8.42 |
| 2024-12-10 | -8.71 |
| 2024-12-09 | -8.52 |
| 2024-12-06 | -8.52 |
| 2024-12-05 | -8.40 |
| 2024-12-04 | -8.67 |
| 2024-12-03 | -7.87 |
| 2024-12-02 | -7.99 |
| 2024-11-29 | -7.99 |
| 2024-11-27 | -8.01 |
| 2024-11-26 | -7.87 |
| 2024-11-25 | -7.89 |
| 2024-11-22 | -8.11 |
| 2024-11-21 | -7.99 |
| 2024-11-20 | -7.94 |
| 2024-11-19 | -8.06 |
| 2024-11-18 | -8.13 |
| 2024-11-15 | -8.42 |
| 2024-11-14 | -8.40 |
| 2024-11-13 | -8.45 |
| 2024-11-12 | -8.42 |
| 2024-11-11 | -8.64 |
| 2024-11-08 | -8.69 |
| 2024-11-07 | -8.64 |
| 2024-11-06 | -9.10 |
| 2024-11-05 | -9.20 |
| 2024-11-04 | -8.98 |
| 2024-11-01 | -9.20 |
| 2024-10-31 | -8.92 |
| 2024-10-30 | -9.15 |
| 2024-10-29 | -9.39 |
| 2024-10-28 | -9.42 |
| 2024-10-25 | -9.22 |
| 2024-10-24 | -9.42 |
| 2024-10-23 | -9.44 |
| 2024-10-22 | -9.37 |
| 2024-10-21 | -9.47 |
| 2024-10-18 | -9.66 |
| 2024-10-17 | -9.59 |
| 2024-10-16 | -9.78 |
| 2024-10-15 | -9.56 |
| 2024-10-14 | -8.96 |
| 2024-10-11 | -9.01 |
| 2024-10-10 | -8.79 |
| 2024-10-09 | -8.71 |
| 2024-10-08 | -8.74 |
| 2024-10-07 | -8.64 |
| 2024-10-04 | -8.91 |
| 2024-10-03 | -8.93 |
| 2024-10-02 | -9.05 |